Jonathan Wosen
STAT
Washington, United States
Contact Jonathan
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Jonathan:
Biotech rents hold firm as demand for lab space slumps
From San Diego to Boston, the biotech industry’s demand for space has lessened as public and private investment in companies has slowed. → Read More
First non-immunosuppressive drug approved for a rare and deadly kidney disease
Travere Therapeutics won accelerated approval for a drug that treats a rare and deadly autoimmune disease that attacks the kidneys and can lead to organ failure. → Read More
‘It is a balance’: Scientists grapple with ethics of cutting-edge stem cell research
Stem cell scientists cautioned that focusing on the potential misuse of their work, rather than the good that can come from it, could be counterproductive. → Read More
Study suggests DNA sequencing could reduce infant deaths, often caused by genetic disease
Researchers sequenced the DNA of 112 infants who died and found that about 40% of them had detectable genetic diseases; in 30% of those cases there were treatments known to be helpful for those conditions. → Read More
New mouse study shows genes aren’t only way to pass obesity to next generation
Rats with fertility issues after their great-great-grandmothers were exposed to pesticides. Mice suffering from obesity and liver disease five generations after an ancestor drank water laced with a chemical used to coat ship hulls. All without detectable genetic changes. → Read More
Chinese DNA giant’s U.S. affiliate looks to rival Illumina, touting $100 genome and high-power sequencers
Complete Genomics, Chinese DNA giant’s U.S. affiliate, looks to rival Illumina, touting $100 genome and high-power sequencers. → Read More
Bay Area biotech uses AI to unlock RNA structures — and find new therapies in the process
A new Bay Area biotech is harnessing artificial intelligence to better understand and predict RNA structures in hopes of developing new therapeutics. → Read More
‘I’m just disgusted’: How alleged sexual misconduct stole one student’s passion for academic science
The story of one Washington University in St. Louis student shows the exodus from the ivory tower isn’t always about money. For some, it’s about leaving an environment they see as abusive and predatory. → Read More
Liquid-biopsy firm Grail is spending more than ever lobbying Congress
Grail spent more than $1 million last quarter lobbying Congress, underscoring the urgency of its bid to secure Medicare coverage for its cancer screening test. → Read More
Liquid biopsy study suggests a better way to decide which colorectal cancer patients need chemo
Bits of tumor DNA adrift in a patient’s blood are an important bellwether for whether cancer will return — and, as a new study shows, can predict which treatments are likely to work. → Read More
Invitae’s new CEO on why the genetic testing firm stopped chasing ‘volume at all costs’
"The industry is learning that almost unlimited access to capital, chasing testing volume and adding cost on the back end, is not sustainable," said Invitae CEO Ken Knight. → Read More
BioNTech CEO lays out vision for how mRNA and AI can power personalized medicine
With the acquisition of machine learning firm InstaDeep, BioNTech is betting that AI will play a key role in the future of mRNA medicines. → Read More
Upstart Element ratchets up race for cheaper DNA sequencing with a $200 genome
Element’s machine can now read a whole human genome for as little as $200 — the cost of a couple trips to the grocery store. → Read More
FDA’s Califf says congressional report on Aduhelm controversy contained “no surprises”
FDA head Robert Califf made his first public comments following a congressional investigation into the agency’s role in approving Aduhelm. → Read More
A flurry of pharma acquisitions kick off JPM week after a slow year for deals
Four life science companies have announced acquisitions worth roughly $4.5 billion in total, raising hopes that 2023 will yield more M&A. → Read More
Fate Therapeutics plans mass layoffs, after early end to cell therapy deal with Janssen
The San Diego-based biotech announced Thursday that the termination of its deal with Janssen will result in layoffs and curtailed drug development. → Read More
Study offers a genetic explanation for why some drugs trigger a deadly brain disease
Researchers uncovered four gene variants connected with the immune system that significantly increase a person’s risk of developing a brain disease known as PML. → Read More
Alzheimer’s researchers try out an unfamiliar sensation: optimism
Scientific meetings about Alzheimer’s disease can be funereal affairs. But this year's Clinical Trials in Alzheimer’s Disease meeting felt markedly different. → Read More
Roche’s failed Alzheimer’s studies lend weight to an emerging idea about potential treatments
Roche’s failed Alzheimer’s studies lend weight to an emerging idea about potential treatments. → Read More
Detailed data on Alzheimer’s therapy from Eisai, Biogen hold up to scientific scrutiny
Lecanemab, a closely watched new treatment for Alzheimer’s from Eisai and Biogen, held up to scrutiny in a detailed scientific presentation Tuesday. → Read More